Affymetrix, a developer of products that accelerate genetic research, has posted its operating results that revealed a negative impact for the second quarter of 2009.
The company’s total revenue for the second quarter of 2009 was $81.6 million, as compared to $86.9 million posted for the second quarter of the prior year, representing a negative currency impact of $3 million.
Affymetrix posted a net income of approximately $7.3 million for the second quarter of 2009, as compared to a net loss of $3.6 million for the same period in 2008.
For the second quarter of 2009, the company’s operating expenses were $52.3 million as compared to $50.1 million posted in the second quarter of the prior year.
Kevin King, chief executive officer of Affymetrix, said: Despite challenging macro-economic conditions, we achieved our financial and operational goals through the first half of 2009. The combination of new product introductions, recent acquisitions, and revenue from partners is expanding our business into the larger markets for validation and routine testing.
During the second quarter of 2009, the company has consolidated array manufacturing in Singapore and reagent manufacturing to Cleveland, Ohio.